杜瓦卢马布
危险系数
癌症
医学
安慰剂
围手术期
多西紫杉醇
四分位间距
胃肠病学
置信区间
内科学
外科
病理
替代医学
免疫疗法
无容量
作者
Yelena Y. Janjigian,Salah-Eddin Al-Batran,Zev A. Wainberg,Kei Muro,Daniela Molena,Eric Van Cutsem,Woo Jin Hyung,Lucjan Wyrwicz,Do-Youn Oh,Takeshi Omori,Markus Moehler,Marcelo Garrido,Sulene Cunha Sousa Oliveira,Moïshe Liberman,Victor Castro Oliden,Elizabeth Smyth,Alexander Stein,Mehmet Bilici,Marcelo Alvarenga,Vadim Kozlov
标识
DOI:10.1056/nejmoa2503701
摘要
Perioperative durvalumab plus FLOT led to significantly better event-free survival outcomes than FLOT alone among participants with resectable gastric or gastroesophageal junction adenocarcinoma. (Funded by AstraZeneca; MATTERHORN ClinicalTrials.gov number, NCT04592913.).
科研通智能强力驱动
Strongly Powered by AbleSci AI